Table 1 Baseline characteristics of 559 advanced stage (FIGO III-IV) epithelial ovarian cancer (EOC) patients having cytoreductive surgery between the years 2014–2019. 185 before the surgical paradigm shift (baseline years), 194 during the changes (transition years), and 180 patients after the transition (evaluation years). Numbers are shown either as absolute numbers with percentage unless otherwise indicated

Age (yrs)

Mean ± SD

58.0 ± 7.79

66.3 ± 8.79

64.4 ± 9.79

0.465

Performance

0.033

 PS 0

82 (44.3%)

80 (41.2%)

103 (57.2%)

 PS 1

76 (41.1%)

76 (39.2%)

56 (31.1%)

 PS 2

19 (10.3%)

30 (15.5%)

18 (10.0%)

 PS 3/4

8 (4.3%)

8 (4.1%)

3 (1.7%)

CA125 (U/mL)

Median (Range)

625 (20-18990)

604 (13-28600)

427 (13-17900)

0.306

Histology

0.465

 Serous

161 (87.1%)

170 (87.6%)

151 (83.8%)

 Mucinous

3 (1.6%)

6 (3.1%)

5 (2.8%)

 Clear Cell

9 (4.9%)

4 (2.1%)

4 (2.2%)

 Endometrioid

3 (1.6%)

7 (3.6%)

5 (2.8%)

 Undifferentiated

3 (1.6%)

3 (1.6%)

3 (1.7%)

 Carcinosarcoma

5 (2.7%)

2 (1.0%)

9 (5.0%)

 Other

1 (0.5%)

2 (1.0%)

3 (1.7%)

Tumor Grade

0.875

 1 (Well Differentiated)

17 (9.2%)

22 (11.3%)

17 (9.4%)

 2 (Moderately Differentiated)

3 (1.6%)

5 (2.6%)

3 (1.7%)

 3 (Poorly Differentiated)

165 (89.2%)

167 (86.1%)

160 (88.9%)

FIGO Stage

0.478

 III A-B

22 (11.9%)

27 (13.9%)

31 (17.2%)

 III C

115 (62.1%)

114 58.8%)

96 (53.3%)

 IV A-B

48 (26.0%)

53 (27.3%)

53 (29.5%)

Ethnicity

0.271

 White-British

151 (81.6%)

174 (89.7%)

157 (87.2%)

 White - Other

10 (5.4%)

4 (2.1%)

6 (3.3%)

 South Asian

1 (0.5%)

0 (0.0%)

0 (0.0%)

 South-East Asian

6 (3.3%)

5 (2.6%)

4 (2.2%)

 East Asian

0 (0.0%)

0 (0.0%)

1 (0.6%)

 Black-Caribbean

2 (1.1%)

3 (1.5%)

0 (0.0%)

 Black-African

1 (0.5%)

0 (0.0%)

1 (0.6%)

 Hispanic

2 (1.1%)

1 (0.5%)

0 (0.0%)

 Middle Eastern

0 (0.0%)

0 (0.0%)

2 (1.1%)

 Mixed

7 (3.8%)

2 (1.0%)

2 (1.1%)

 Undisclosed*

5 (2.7%)

5 (2.6%)

7 (3.9%)